Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Margolis

Showing results (201-210 of 219) with videos related to

Pageof 22
Sort By:
Plos One|December 8, 2022
Evaluation of a COVID-19 convalescent plasma program at a U.S. academic medical centerHeather B Root, Matt Gilleskie, Chih-Huan Lu, et al.
Scientific Reports|March 22, 2020
Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 InfectionCynthia L Gay, Joann D Kuruc, Shane D Falcinelli, et al.
The Journal of Clinical Investigation|July 20, 2018
HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollersRadwa Sharaf, Guinevere Q Lee, Xiaoming Sun, et al.
The Journal of Infectious Diseases|September 25, 2021
Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent VorinostatCynthia L Gay, Katherine S James, Marina Tuyishime, et al.
Science (New York, N.Y.)|November 13, 2020
SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivoYixuan J Hou, Shiho Chiba, Peter Halfmann, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 6, 2023
HIV post-treatment controllers have distinct immunological and virological featuresBehzad Etemad, Xiaoming Sun, Yijia Li, et al.
Plos Medicine|July 8, 2009
Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infectionMarc C Levesque, M Anthony Moody, Kwan-Ki Hwang, et al.
Nature Medicine|October 2, 2023
AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaquesAmir Dashti, Sophia Sukkestad, Anna M Horner, et al.
The Journal of Clinical Investigation|June 15, 2023
Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapyYuyang Tang, Antoine Chaillon, Sara Gianella, et al.
The Journal of Clinical Investigation|September 29, 2015
Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cellsJulia A M Sung, Joy Pickeral, Liqin Liu, et al.
Pageof 22

Showing results (201-210 of 219) with videos related to

Sort By:
Pageof 22
Plos One|December 8, 2022
Evaluation of a COVID-19 convalescent plasma program at a U.S. academic medical centerHeather B Root, Matt Gilleskie, Chih-Huan Lu, et al.
Scientific Reports|March 22, 2020
Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 InfectionCynthia L Gay, Joann D Kuruc, Shane D Falcinelli, et al.
The Journal of Clinical Investigation|July 20, 2018
HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollersRadwa Sharaf, Guinevere Q Lee, Xiaoming Sun, et al.
The Journal of Infectious Diseases|September 25, 2021
Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent VorinostatCynthia L Gay, Katherine S James, Marina Tuyishime, et al.
Science (New York, N.Y.)|November 13, 2020
SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivoYixuan J Hou, Shiho Chiba, Peter Halfmann, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 6, 2023
HIV post-treatment controllers have distinct immunological and virological featuresBehzad Etemad, Xiaoming Sun, Yijia Li, et al.
Plos Medicine|July 8, 2009
Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infectionMarc C Levesque, M Anthony Moody, Kwan-Ki Hwang, et al.
Nature Medicine|October 2, 2023
AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaquesAmir Dashti, Sophia Sukkestad, Anna M Horner, et al.
The Journal of Clinical Investigation|June 15, 2023
Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapyYuyang Tang, Antoine Chaillon, Sara Gianella, et al.
The Journal of Clinical Investigation|September 29, 2015
Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cellsJulia A M Sung, Joy Pickeral, Liqin Liu, et al.
Pageof 22